The upcoming earnings report for Enovis Corporation (ENOV) is scheduled for Wednesday, May 6th. Analysts expect an earnings per share of $0.82.
Enovis Corporation is currently priced at $23.81, showing a decrease of 73 cents (-2.97%) from the previous close of $24.54. The trading volume is $83,099, which is 8.28% relative to the average volume.
In the latest quarterly earnings report on Wednesday, February 25th, ENOV reported an earnings per share of $0.95, exceeding the consensus estimate of $0.81. However, the company faced a net loss of $520.59 million.
Enovis Corporation's cash flow indicates positive free cash flow of $32.29 million and a net change in cash of $2.77 million. Operating cash flow is reported at $88.54 million.
The company generated $575.76 million in revenue with a gross profit of $349.42 million. Operating expenses totaled $896.69 million, resulting in a net loss of $520.59 million.
Key financial metrics show a negative net profit margin (-90.42%) and return on equity (-34.95). The debt ratio stands at 35.97%, with a price-to-sales ratio of 2.63.
Enovis Corporation holds total assets of $3.83 billion, with total liabilities at $2.34 billion. The company has a net debt position of $1.34 billion.
This real-time financial report reflects a challenging period for ENOV, with declining performance and profitability. Investors should closely monitor upcoming earnings to gauge the company's future trajectory.
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.